Inhibitex to Present at the Lazard Life Sciences Conference
ATLANTA, GA -- 11/19/2004 -- Inhibitex, Inc. (NASDAQ: INHX) announced today that it will present at the Lazard Life Sciences Conference on Tuesday, November 30, 2004 at 2:30 p.m. EST from the Mandarin Oriental in New York. William D. Johnston, Ph.D., president and chief executive officer of Inhibitex will provide an update on the company, including its advanced clinical development programs for Veronate and Aurexis.
The live audio webcast of the presentation will be available on the “Investors” section of the Company’s website, www.inhibitex.com. This webcast will be archived and available on the Inhibitex website after the event for a period of 30 days.
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. The Company currently has five drug development programs, all of which are based on its proprietary MSCRAMM protein platform technology. The Company’s most advanced product candidates are Veronate and Aurexis, both of which the Company has retained all worldwide rights to. Both Veronate and Aurexis have been granted Fast Track designation by the FDA. The Company’s preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines.
Inhibitex®, MSCRAMM®, Veronate® and Aurexis® are registered trademarks of Inhibitex, Inc.
- Contact Information
- Kathryn Morris
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.